Cannabis related side effects in otolaryngology: a scoping review.
Adverse effects
Cannabis
Head and neck
Hearing loss
Scoping review
Sinusitis
Voice
Journal
Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
ISSN: 1916-0216
Titre abrégé: J Otolaryngol Head Neck Surg
Pays: England
ID NLM: 101479544
Informations de publication
Date de publication:
27 Sep 2021
27 Sep 2021
Historique:
received:
02
03
2021
accepted:
05
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Cannabis has been rapidly legalized in North America; however, limited evidence exists around its side effects. Health Canada defines side effect as a harmful and unintended response to a health product. Given drug safety concerns, this study's purpose was to review the unintended side effects of cannabis in otolaryngology. The Preferred Reporting Items For Systematic Reviews and Meta-analysis extension for Scoping Reviews (PRISMA-ScR) protocol was used to conduct a scoping review of the MEDLINE, EMBASE, CINAHL, and CENTRAL databases. (PROSPERO: CRD42020153022). English studies in adults were included from inception to the end of 2019. In-vitro, animal, and studies with n < 5 were excluded. Primary outcome was defined as unintended side effects (defined as any Otolaryngology symptom or diagnosis) following cannabis use. Oxford Centre for Evidence-Based Medicine: Levels of Evidence and risk of bias using the Risk of Bias in randomized trials (RoB 2) and Risk of Bias in Non-Randomized Studies of Interventions (ROBINS-I) tools were assessed.. Two authors independently reviewed all studies; the senior author settled any discrepancies. Five hundred and twenty-one studies were screened; 48 studies were analysed. Subspecialties comprised: Head and Neck (32), Otology (8), Rhinology (5), Airway (5), Laryngology (1). Cannabis use was associated with unintended tinnitus, vertigo, hearing loss, infection, malignancy, sinusitis, allergic rhinitis, thyroid dysfunction, and dyspnea. About half (54.1%) of studies showed increased side effects, or no change in symptoms following cannabis use. Oxford Levels of Evidence was 2-4 with substantial heterogeneity. Risk of bias assessment with RoB2 was low to high and ROBINS-1 was moderate to critical. This was the first comprehensive scoping review of unintended side effects of cannabis in Otolaryngology. The current literature is limited and lacks high-quality research Future randomized studies are needed to focus on therapeutic effects of cannabis in otolaryngology. Substantial work remains to guide clinicians to suggest safe, evidence-based choices for cannabis use.
Sections du résumé
BACKGROUND
BACKGROUND
Cannabis has been rapidly legalized in North America; however, limited evidence exists around its side effects. Health Canada defines side effect as a harmful and unintended response to a health product. Given drug safety concerns, this study's purpose was to review the unintended side effects of cannabis in otolaryngology.
METHODS
METHODS
The Preferred Reporting Items For Systematic Reviews and Meta-analysis extension for Scoping Reviews (PRISMA-ScR) protocol was used to conduct a scoping review of the MEDLINE, EMBASE, CINAHL, and CENTRAL databases. (PROSPERO: CRD42020153022). English studies in adults were included from inception to the end of 2019. In-vitro, animal, and studies with n < 5 were excluded. Primary outcome was defined as unintended side effects (defined as any Otolaryngology symptom or diagnosis) following cannabis use. Oxford Centre for Evidence-Based Medicine: Levels of Evidence and risk of bias using the Risk of Bias in randomized trials (RoB 2) and Risk of Bias in Non-Randomized Studies of Interventions (ROBINS-I) tools were assessed.. Two authors independently reviewed all studies; the senior author settled any discrepancies.
RESULTS
RESULTS
Five hundred and twenty-one studies were screened; 48 studies were analysed. Subspecialties comprised: Head and Neck (32), Otology (8), Rhinology (5), Airway (5), Laryngology (1). Cannabis use was associated with unintended tinnitus, vertigo, hearing loss, infection, malignancy, sinusitis, allergic rhinitis, thyroid dysfunction, and dyspnea. About half (54.1%) of studies showed increased side effects, or no change in symptoms following cannabis use. Oxford Levels of Evidence was 2-4 with substantial heterogeneity. Risk of bias assessment with RoB2 was low to high and ROBINS-1 was moderate to critical.
CONCLUSION
CONCLUSIONS
This was the first comprehensive scoping review of unintended side effects of cannabis in Otolaryngology. The current literature is limited and lacks high-quality research Future randomized studies are needed to focus on therapeutic effects of cannabis in otolaryngology. Substantial work remains to guide clinicians to suggest safe, evidence-based choices for cannabis use.
Identifiants
pubmed: 34579787
doi: 10.1186/s40463-021-00538-6
pii: 10.1186/s40463-021-00538-6
pmc: PMC8474823
doi:
Substances chimiques
Analgesics
0
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
56Informations de copyright
© 2021. The Author(s).
Références
J Allergy Clin Immunol. 1983 Apr;71(4):389-93
pubmed: 6833678
Cancer Res. 2004 Jun 1;64(11):4049-54
pubmed: 15173020
Lancet Psychiatry. 2016 Oct;3(10):954-964
pubmed: 27592339
Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):160-71
pubmed: 24351902
Sleep. 2018 Jan 1;41(1):
pubmed: 29121334
J Oral Pathol Med. 2004 Oct;33(9):525-32
pubmed: 15357672
Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1071-8
pubmed: 10613339
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
J Clin Sleep Med. 2018 Apr 15;14(4):679-681
pubmed: 29609727
J Infect Dis. 2015 Sep 1;212(5):760-8
pubmed: 25681375
Ann Epidemiol. 2010 Apr;20(4):289-97
pubmed: 20171900
Arch Otolaryngol. 1972 Mar;95(3):248-51
pubmed: 5013269
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1829-34
pubmed: 17035389
J Otolaryngol Head Neck Surg. 2019 Sep 2;48(1):43
pubmed: 31477184
JAMA Otolaryngol Head Neck Surg. 2019 Oct 1;145(10):956-964
pubmed: 31393535
Pharmacopsychiatry. 2013 Jan;46(1):35-6
pubmed: 22821384
J Otolaryngol Head Neck Surg. 2018 Nov 22;47(1):73
pubmed: 30466476
Braz J Otorhinolaryngol. 2012 Oct;78(5):90-6
pubmed: 23108826
Tumour Biol. 2015 Aug;36(8):6029-36
pubmed: 25736926
Sex Transm Dis. 2014 Aug;41(8):486-92
pubmed: 25013976
Arch Oral Biol. 2015 Dec;60(12):1750-5
pubmed: 26433192
SADJ. 2002 Apr;57(4):132-5
pubmed: 12078330
J Otolaryngol. 1976 Jun;5(3):233-7
pubmed: 933252
South Med J. 1988 Oct;81(10):1213-6
pubmed: 3175726
Oral Oncol. 2004 Mar;40(3):304-13
pubmed: 14747062
Otolaryngol Head Neck Surg. 2008 Mar;138(3):374-80
pubmed: 18312888
J Natl Cancer Inst. 2008 Mar 19;100(6):407-20
pubmed: 18334711
Neuropsychopharmacology. 2011 Jun;36(7):1340-8
pubmed: 21412224
Am J Otolaryngol. 2019 Sep - Oct;40(5):770-775
pubmed: 31174932
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Ear Nose Throat J. 1980 Dec;59(12):506-9
pubmed: 7227255
J Clin Pharmacol. 1973 May-Jun;13(5):214-7
pubmed: 4541160
J Oral Pathol Med. 1990 Aug;19(7):319-21
pubmed: 2231436
J Speech Lang Hear Res. 2019 Sep 20;62(9):3500-3515
pubmed: 31525116
Sci Rep. 2019 Sep 3;9(1):12697
pubmed: 31481657
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Hum Exp Toxicol. 2002 Jun;21(6):289-92
pubmed: 12195931
N Engl J Med. 2014 Jun 5;370(23):2219-27
pubmed: 24897085
Clin Neurophysiol. 2008 Feb;119(2):321-31
pubmed: 18065267
Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1544-51
pubmed: 19423532
Community Dent Oral Epidemiol. 1993 Apr;21(2):78-81
pubmed: 8485974
Cancer Prev Res (Phila). 2009 Aug;2(8):759-68
pubmed: 19638490
Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1043-9
pubmed: 11045786
Ann Allergy Asthma Immunol. 2000 Sep;85(3):238-40
pubmed: 11030280
Laryngoscope. 1974 May;84(5):816-20
pubmed: 4545296
Otolaryngol Head Neck Surg. 1986 Apr;94(4):517-21
pubmed: 3012440
Front Psychiatry. 2013 Jan 22;4:1
pubmed: 23346060
JAMA. 1971 Jun 21;216(12):1965-9
pubmed: 5108626
JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):312-6
pubmed: 24526276
Thyroid. 2017 Feb;27(2):167-173
pubmed: 27799014
COPD. 2012 Aug;9(4):367-74
pubmed: 22497563
Br J Cancer. 2009 Oct 6;101(7):1207-12
pubmed: 19724280
Br J Ind Med. 1990 Sep;47(9):627-32
pubmed: 2207034
West Indian Med J. 1983 Jun;32(2):101-5
pubmed: 6613099